Ecuadorians benefit from Cuban drug Heberprot-p
The Cuban drug Heberprot-p, a novel cure for the diabetic foot ulcer, has been warmly received in Ecuador, following very positive results reported by patients undertaking the treatment in that South American country.
On Monday, local newspaper El Telegrafo echoed the authorities and patients' satisfaction with the Cuban drug, which has is also undergoing a test period in European Union member countries and Eastern European nations.
The drug has been highly praised as it has recorded great results in the prevention of amputation of the lower extremities.
In Ecuador, the medicine is provided free in public hospitals in the provinces of Chimborazo, Santo Domingo, Azuay, Loja, Imbabura, Pichincha, Guayas and Manabi.
The medicine prevents complications of diabetic foot ulcers, that affects more than six percent of the national population, causes disability, and is one of the five most common complaints in that country.
The formula is based on Human Epidermal Growth Factor Recombinant Heberprot-p 75 and it was developed at the Center for Genetic Engineering and Biotechnology in Cuba.